# Geoff Cook (Noom CEO) - The future of compounded GLP-1s

Page: https://stenobird.com/podcast/hims-house-7026583/geoff-cook-noom-ceo-the-future-of-compounded-glp-1s
Text version: https://stenobird.com/podcast/hims-house-7026583/geoff-cook-noom-ceo-the-future-of-compounded-glp-1s.md
Podcast: [Hims House](https://stenobird.com/podcast/hims-house-7026583)
Published: 2025-09-04T13:28:52+00:00
Episode link: https://podcasters.spotify.com/pod/show/jonathan-stern1/episodes/Geoff-Cook-Noom-CEO---The-future-of-compounded-GLP-1s-e3egql7
Audio file: https://anchor.fm/s/10e9c0874/podcast/play/114894951/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-1-2%2F417288032-44100-2-40b7bedd16220377.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/hims-house-7026583/episodes/geoff-cook-noom-ceo-the-future-of-compounded-glp-1s
Duration seconds: 3254

## Resource

In Episode 44 of Hims House, hosts Jonathan Stern and Patrick Lester (Bayside) sit down with Geoff Cook, CEO of Noom. Noom is one of Hims' competitors and is best known for its behavioral health platform and recent expansion into GLP-1 microdosing and hormone replacement therapy. Geoff discusses Noom’s evolution, the shift in revenue from behavioral programs to medicated plans, and the company’s vision for democratizing longevity medicine. The conversation covers the business of GLP-1s, regulatory and legal challenges, the impact of tariffs and partnerships, and the future of personalized healthcare. The episode closes with predictions for the next decade in health tech and reflections on human flourishing. Link to the article about the "high-priced drug list" : https://www.mmm-online.com/news/noom-wsj-ad-policy-changes-compounded-glp-1 00:00 - Introduction 01:11 - Noom’s background and evolution 05:17 - Noom's revenue breakdown: behavioral vs. medicated programs 07:22 - Launch of GLP-1 microdosing 17:44 - Geoff’s personal experience with microdosing 21:12 - Policy and regulatory landscape for GLP-1s 24:19 - Compounding, MFN pricing, and drug shortages 28:38 - Noom's WSJ ad for high-priced drug list 31:36 - Supply chain and tariffs on APIs 34:10 - Partnerships with pharma (Lilly, Novo) 37:11 - Legal risks and the future of healthcare “front doors” 40:36 - Hims' core business slowdown: competition and ad policy 45:21 - Noom’s strategy for growth... free tier? 46:06 - Looking ahead: AI, peptides, and the future of health tech 53:52 - Reflections on human flourishing Get full access to Hims House at himshouse.substack.com/subscribe

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/hims-house-7026583/episodes/geoff-cook-noom-ceo-the-future-of-compounded-glp-1s/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/hims-house-7026583/geoff-cook-noom-ceo-the-future-of-compounded-glp-1s.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.